Spruce Biosciences, Inc.
sprucebio.comWhat Do They Do?
Develops therapies for neurological disorders, including an investigational enzyme replacement therapy for people with Sanfilippo syndrome type B.
10-K for FY2025, filed Mar 9, 2026
Who Are Their Customers?
The company plans to commercialize TA-ERT for people with Sanfilippo syndrome type B through its own organization in the United States, EU, and UK, and through collaborators and distributors in other markets.
10-K for FY2025, filed Mar 9, 2026Seek regulatory approval and maximize the U.S. commercial potential of TA-ERT for the treatment of MPS IIIB. We intend to seek U.S.…View ↗
Commercialize globally through a patient-focused organization. We seek to commercialize TA-ERT and its other investigational products…View ↗
We are in the process of scaling up a commercial organization for the marketing, sales, and distribution of pharmaceutical products. We are…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$16.2MView ↗
- ▲ +685% (Loss)
- vs −$2.1M in Q2 FY2025
-
Mar 20, 2026
Spruce and Kaken agreed to end their tildacerfont Japan collaboration
The termination ends Kaken’s Japan rights and removes Spruce’s eligibility for unearned milestones and royalties.
Sources
8-K, filed Mar 20, 2026
On March 16, 2026, Spruce Biosciences, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kaken…View ↗
Program focus The latest report centers the company on TA-ERT for Sanfilippo syndrome type B, while the older report focused on tildacerfont for classic congenital adrenal hyperplasia.
Loading...
